Moderna vs BIO-TECHNE (MRNA vs TECH)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Moderna is the larger company by revenue ($1.9B vs $1.2B) and market value ($61.6B vs $11.3B). BIO-TECHNE has grown revenue faster over the last 4 fiscal years (+9.9% cumulative vs -89.5%).
About Moderna
Moderna, Inc. develops medicines based on messenger RNA (mRNA) technology to treat and prevent diseases. Its main products include COVID-19 vaccines Spikevax and mNEXSPIKE, and the respiratory syncytial virus vaccine mRESVIA. The company serves patients globally and is advancing a pipeline of vaccines and therapies for infectious diseases, oncology, and rare diseases.
About BIO-TECHNE
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments: Protein Sciences, which provides biological reagents and protein analysis tools for research and therapeutic development, and Diagnostics and Spatial Biology, which offers diagnostic assays, spatial biology solutions, and molecular diagnostic products. Bio-Techne serves customers including academic researchers, pharmaceutical and biotech companies, and clinical diagnostic laboratories.
Head to head (MRNA FY2025 vs TECH FY2026)
| Metric | MRNAFY2025 | TECHFY2026 |
|---|---|---|
| Revenue | $1.94B | $1.22B |
| Revenue growth (YoY) | -39.9% | -0.4% |
| Gross margin | — | 65.8% |
| Operating margin | — | 20.7% |
| Net margin | — | 15.0% |
| Net income | $-2.82B | $181.9M |
| Diluted EPS | $-7.26 | $1.16 |
| FCF margin | — | 21.7% |
| ROE | -32.6% | 8.6% |
| Long-term debt / equity | 0.07× | 0.09× |
| Market cap | $61.59B | $11.35B |
| P/E | — | 62.4× |
Fundamentals are from each company’s SEC filings (MRNA FY2025, TECH FY2026). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| MRNA by fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18.47B | $19.26B | $6.85B | $3.24B | $1.94B |
| Net income | $12.20B | $8.36B | $-4.71B | $-3.56B | $-2.82B |
| Operating margin | 72.0% | 48.9% | -61.9% | — | — |
| TECH by fiscal year | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Net income | $263.1M | $285.4M | $168.1M | $73.4M | $181.9M |
| Operating margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
Moderna and BIO-TECHNE use different fiscal calendars (MRNA's FY2025 ended 2025-12-31, TECH's FY2026 ended 2026-06-30), so their fiscal years are shown separately rather than forced into one timeline.
Peer standing
Where each company ranks among the 71 biotech companies, on the same scale. Each figure is ranked only against peers that report it. Percentiles describe position in the distribution, not a rating.
| Metric | MRNA | TECH |
|---|---|---|
| Revenue growth (YoY) | -39.9%14th percentile of 64 | -0.4%30th percentile of 64 |
| ROE | -32.6%47th percentile of 61 | 8.6%78th percentile of 61 |
| Long-term debt / equity | 0.07×16th percentile of 20 | 0.09×21st percentile of 20 |
| Short interest (days to cover) | 9.15d60th percentile of 71 | 2.27d7th percentile of 71 |
Short interest
| FINRA settlement data | MRNA | TECH |
|---|---|---|
| Shares sold short | 52.8M | 6.5M |
| Change vs prior settlement | +6.1% | -30.3% |
| Days to cover | 9.15 | 2.27 |
| As of settlement | 2026-08-14 | 2026-08-14 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | MRNA | TECH |
|---|---|---|
| Buys | 0 | 0 |
| Sells | 7 ($35.2M) | 0 |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
6 tracked 13F managers hold both Moderna and BIO-TECHNE as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs MRNABIIB vs MRNAEXEL vs MRNAGILD vs MRNAMRNA vs NBIXMRNA vs RVMDAll biotech stocks →All comparisons →
Track MRNA and TECH
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.